Zentalis Pharmaceuticals Inc
ZNTL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$123.66M
Close$
$-0.05
102.8% downside
Current Fair Value
102.8% downsideOvervalued by 102.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $123.66 Million |
|---|---|
| Enterprise Value | $132.44 Million |
| Earnings per Share | $-1.91 |
| Beta | 1.94 |
| Outstanding Shares | 70,264,000 |
Return
| Return on Equity | -121.76% |
|---|---|
| Return on Assets | -81.22% |
| Return on Invested Capital | -100.99% |
Valuation & Multiples
| P/E Ratio | -0.8 |
|---|---|
| PEG | -0.42 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.47
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.61
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 67.64% |
|---|---|
| Total Invested | $85,398▼ 99.96% |
| Investors Holding | 4▼ 119.00% |
About Zentalis Pharmaceuticals Inc
124 employees
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeli...